Capricor Therapeutics (CAPR) Stock Forecast: StockMap's 2-Week Call
CAPR stock forecast: StockMap's model leans Outperform on Capricor Therapeutics for the two weeks after the Nov 13 close, toward CAPR doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 2 of 3 two-week windows on CAPR since Sep 24; by chance, a call on the same dates was right 51% of the time.
Capricor Therapeutics last closed at $9.53, -6.93% on the session.
Against the IVW growth benchmark the position is -6.02% over the forecast window.
Capricor Therapeutics' market cap is $554.11M as of November 13, 2026.
Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 21 (too close to call).
Where CAPR sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 7 bullish and 8 bearish.
Agreement across those insights is 47%.
14 daily calls for CAPR so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Capricor Therapeutics in the 17th percentile on return on equity, where 100 is best.
Capricor Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Capricor Therapeutics as the 166th largest of the 391 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 186 Moderate Underperform, 157 Neutral, 33 Strong Underperform and 15 Moderate Outperform.
On that composite Capricor Therapeutics ranks 14th of 391 in the group, against a group median of -0.24.